Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Unspecified Adult Solid Tumor, Protocol Specific clinical trials
5 of 112 indexed Unspecified Adult Solid Tumor, Protocol Specific trials are currently recruiting.
112 US clinical trials · 5 currently recruiting
Unspecified Adult Solid Tumor, Protocol Specific is the subject of 112 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 10 are in Phase 3-4 (later-stage) and 93 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 26 of these trials.
The research picture
Unspecified Adult Solid Tumor, Protocol Specific has 112 registered US clinical trials, 5 of them open to new participants right now, about 4% of the total.
- 5
- recruiting participants now
- 4%
- of trials open to enrollment
- 10
- in Phase 3–4 (later-stage)
- 26
- top sponsor: National Cancer Institute (NCI)
Active & Recent Trials
112 total, page 2 of 3
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
Mayo Clinic
NCT00949949
Stereotactic Body Radiation Therapy and Vertebroplasty in Treating Patients With Localized Spinal Metastasis
University of Texas Southwestern Medical Center
NCT00855803
Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors
Case Comprehensive Cancer Center
NCT00253344
Sirolimus in Treating Patients With Metastatic or Unresectable Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00368914
Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT00423865
Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors
University of California, Davis
NCT00389584
Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors
University of Nebraska
NCT01206465
Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients
Pfizer
NCT01337765
O(6)-Benzylguanine and Carmustine in Treating Patients With Solid Tumors
Case Comprehensive Cancer Center
NCT00002604
BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT00022529
Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy
Northwestern University
NCT01898130
1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors
National Cancer Institute (NCI)
NCT01191216
Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity
City of Hope Medical Center
NCT00825201
Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
Edward Kim
NCT01924260
Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers
Roswell Park Cancer Institute
NCT01497392
Combination Chemotherapy With or Without Filgrastim in Treating Patients With Advanced Solid Tumors
University of Pittsburgh
NCT00008125
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
City of Hope Medical Center
NCT00544284
Perillyl Alcohol in Treating Patients With Refractory Cancer
National Cancer Institute (NCI)
NCT00002862
Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer
Yale University
NCT00002950
Decitabine in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT00030615
Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer
Roswell Park Cancer Institute
NCT00003294
Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors
National Cancer Institute (NCI)
NCT00079352
Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors
Georgetown University
NCT00003125
3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Recurrent Tumors
Fox Chase Cancer Center
NCT01470365
Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors
National Cancer Institute (NCI)
NCT00112476
ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer
National Institutes of Health Clinical Center (CC)
NCT00387608
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Case Comprehensive Cancer Center
NCT00006465
Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
California Cancer Consortium
NCT00387504
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer
University of Chicago
NCT00002939
An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function
Eisai
NCT01418677
Calcitriol, Ketoconazole, and Dexamethasone in Treating Patients With Metastatic or Unresectable Solid Tumors
Roswell Park Cancer Institute
NCT00238225
Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid Tumors
University of Southern California
NCT01957995
SU6668 in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT00024206
BMS-599626 in Treating Patients With Metastatic Solid Tumors
Jonsson Comprehensive Cancer Center
NCT00093730
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
National Cancer Institute (NCI)
NCT00002759
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
NYU Langone Health
NCT00004002
Indole-3-Carbinol in Preventing Cancer in Healthy Participants
University of Kansas
NCT00100958
Patient Education in Preventing Nausea and Vomiting in Cancer Patients Receiving Chemotherapy
University of Rochester
NCT00005994
Vaccine Therapy in Treating Patients With Metastatic Cancer
National Cancer Institute (NCI)
NCT00021164
BMS-247550 and Gemcitabine in Treating Patients With Advanced Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT00043095
3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer
Vion Pharmaceuticals
NCT00016874
BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy
National Cancer Institute (NCI)
NCT00020371
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer
National Cancer Institute (NCI)
NCT00019656
UCN-01 in Treating Patients With Advanced Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00003289
SU5416, Irinotecan, and Cisplatin in Treating Patients With Advanced Solid Tumors
Ohio State University Comprehensive Cancer Center
NCT00006000
Perifosine in Treating Patients With Advanced Solid Tumors
University of Wisconsin, Madison
NCT00005794
Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors
Dartmouth-Hitchcock Medical Center
NCT00014261
Vaccine Therapy in Treating Patients With Advanced Cancer
Jonsson Comprehensive Cancer Center
NCT00004881
PS-341 in Treating Patients With Advanced Cancer
Mayo Clinic
NCT00006362
Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT00004059
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 85 |
| Phase 2 | 8 |
| Phase 3 | 10 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Unspecified Adult Solid Tumor, Protocol Specific Trial Landscape
112 indexed Unspecified Adult Solid Tumor, Protocol Specific studies · 5 recruiting (4%).
Phase mix: 10 late (III/IV) vs 93 early (I/II).
Top sponsor: National Cancer Institute (NCI) (26 trials), 9 others listed. 50 shown below, recruiting first.
How to read this condition's trial landscape
That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation, eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Unspecified Adult Solid Tumor, Protocol Specific?
PlainTrial tracks 112 US clinical trials for Unspecified Adult Solid Tumor, Protocol Specific, of which 5 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Unspecified Adult Solid Tumor, Protocol Specific?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.